Larimar Regulatory Monday, November 16, 2026 +0.40 Positive

Larimar completes BLA for FA drug nomlabofusp

The company submitted a rolling BLA seeking accelerated approval using skin frataxin as a surrogate endpoint, maintaining cash runway into Q2 2027. This move positions the therapy as a potential disease-modifying treatment for Friedreich's ataxia.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed